

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease



Neil A. Zakai, MD,^{a,b} Jessica Minnier, PhD,^c Monika M. Safford, MD,^d Insu Koh, PhD,^a Marguerite R. Irvin, PhD,^e Sergio Fazio, MD, PhD,^f Mary Cushman, MD,^{a,b} Virginia J. Howard, PhD,^e Nathalie Pamir, PhD^f

ABSTRACT

BACKGROUND Plasma lipids are risk factors for coronary heart disease (CHD) in part because of race-specific associations of lipids with CHD.

OBJECTIVES The purpose of this study was to understand why CHD risk equations underperform in Black adults.

METHODS Between 2003 and 2007, the REGARDS (REasons for Geographic and Racial Differences in Stroke) cohort recruited 30,239 Black and White individuals aged ≥ 45 years from the contiguous United States. We used Cox regression models adjusted for clinical and behavioral risk factors to estimate the race-specific hazard of plasma lipid levels with incident CHD (myocardial infarction or CHD death).

RESULTS Among 23,901 CHD-free participants (57.8% White and 58.4% women, mean age 64 ± 9 years) over a median 10 years of follow-up, 664 and 951 CHD events occurred among Black and White adults, respectively. Low-density lipoprotein cholesterol and triglycerides were associated with increased risk of CHD in both races (P interaction by race > 0.10). For sex-specific clinical HDL-C categories: low HDL-C was associated with increased CHD risk in White (HR: 1.22; 95% CI: 1.05-1.43) but not in Black (HR: 0.94; 95% CI: 0.78-1.14) adults (P interaction by race = 0.08); high HDL-C was not associated with decreased CHD events in either race (HR: 0.96; 95% CI: 0.79-1.16 for White participants and HR: 0.91; 95% CI: 0.74-1.12 for Black adults).

CONCLUSIONS Low-density lipoprotein cholesterol and triglycerides modestly predicted CHD risk in Black and White adults. Low HDL-C was associated with increased CHD risk in White but not Black adults, and high HDL-C was not protective in either group. Current high-density lipoprotein cholesterol-based risk calculations could lead to inaccurate risk assessment in Black adults. (J Am Coll Cardiol 2022;80:2104-2115) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Coronary heart disease (CHD) remains a leading cause of morbidity and mortality in the United States, accounting for approximately 13% of all deaths in 2017.¹ Black Americans have a lower risk of overall CHD, although fatal CHD events are more common compared with White

Americans.²⁻⁴ Despite heterogeneity by race in the frequency of CHD risk factors and CHD outcomes, little is known as to the specific reasons for this disparity; thus, the American Heart Association, the U.S. Department of Health and Human Services, and the Institute of Medicine have called for further



Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on www.jacc.org/journal/jacc.

From the ^aDepartment of Medicine, Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; ^bLarner College of Medicine, University of Vermont, Burlington, Vermont, USA; ^cOHSU-PSU School of Public Health, Oregon Health and Science University, Portland, Oregon, USA; ^dGeneral Internal Medicine, Weill Cornell Medicine, New York, New York, USA; ^eDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; and the ^fKnight Cardiovascular Institute, Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received August 8, 2022; accepted September 6, 2022.

community-based populations studies addressing this knowledge gap.⁵⁻⁸

Clinical risk factors for CHD include dyslipidemia, diabetes mellitus, hypertension, adiposity, cigarette smoking, and physical inactivity.⁹ Growing evidence indicates that some of these risk factors display race-specific associations with CHD among Black Americans.¹⁰⁻¹³ Therefore, available risk assessment models, developed primarily in cohorts of White Europeans, may misclassify risk in Black adults,² potentially hindering optimal cardiovascular disease prevention and management programs for this group.

In the 1970s, the Framingham Heart Study discovered the now well-established inverse and linear association between plasma high-density lipoprotein cholesterol (HDL-C) concentration and CHD risk.¹⁴

SEE PAGE 2116

The association was confirmed in other mostly White European cohorts,¹⁵⁻¹⁹ whereas it was weaker²⁰⁻²² or even absent²³⁻²⁵ in racially diverse cohorts. For example, in a subcohort with incident cancer of the REGARDS (Reasons for Geographic and Racial Differences in Stroke) (the same biracial cohort we have investigated in this study), low HDL-C levels (30-40 mg/dL) were associated with reduced risk of incident CHD in Black adults.²⁶ However, this analysis did not examine the association with higher HDL-C levels—an important question considering that in some cohorts (mostly Caucasian), very high HDL-C levels are directly associated with CHD risk.²⁷ Data from >300,000 multiethnic participants in the Emerging Risk Factors Collaboration challenged the understanding of a linear inverse association between HDL-C and CHD even further by demonstrating that individuals with HDL-C <40 mg/dL (the clinical threshold for low HDL-C for men) have increased risk of cardiovascular events, whereas those with levels >60 mg/dL are not afforded protection.²⁸ Because these studies did not focus on race differences, the need remains to determine whether clinical risk categories for CHD using HDL-C levels are appropriate for all people.

To determine whether lipid parameters predicted CHD risk in a contemporary population of Black and White Americans, we assessed the impact of race on the association of lipid levels with incident CHD in REGARDS (**Central Illustration**).

METHODS

STUDY POPULATION. REGARDS is a national prospective cohort of 30,239 participants that was designed to examine potential reasons underlying

regional and racial differences in stroke mortality. Details on the design and methods of REGARDS have been previously described.^{29,30} Briefly, REGARDS is composed of community-dwelling Black and White women and men aged ≥ 45 years, identified via mail and telephone using commercially available lists of U.S. residents, and enrolled from 2003 to 2007. The final sample included 21% of participants from the “stroke buckle” (counties within the coastal plain of North Carolina, South Carolina, and Georgia), 35% from the rest of the southeastern U.S. “stroke belt” (North Carolina, South Carolina, Georgia, Tennessee, Alabama, Mississippi, Arkansas, and Louisiana), and 44% from elsewhere in the contiguous United States. The resulting cohort was 42% Black and 55% women. Exclusion criteria included race other than White or Black, active treatment for cancer in the previous year, chronic medical conditions precluding long-term participation, cognitive impairment, current or impending residence in a nursing home, or inability to communicate in English. An initial telephone interview was used to survey participants, establish eligibility, and obtain verbal consent.³¹ Demographic information and medical history (including risk factor evaluation) was collected by computer-assisted telephone interview.³¹ Race was self-classified by participants and included the following options: White or Black/African American (referred henceforth as Black). An in-home examination was conducted to perform anthropometric measurements (eg, blood pressure) an electrocardiogram, medication inventory, phlebotomy, urine collection, and written informed consent. Follow-up telephone interviews are performed every 6 months to detect possible cardiovascular events. The study was approved by the Institutional Review Boards of all participating institutions. To report the clinical variables, we followed the STROBE (Strengthening The Reporting of OBServational studies in Epidemiology) guidelines.³²

CHD OUTCOMES. Baseline CHD was defined as either participant-reported history of CHD or diagnostic electrocardiographic changes at baseline. Incident CHD was defined as a definite or probable nonfatal myocardial infarction (MI) or CHD death after the baseline in-person visit or on or before December 31, 2017.³³ The definition of “CHD death” includes definite or probable fatal MI (expert-adjudicated, with death within 28 days from event) or death from MI not meeting the criteria for definite, probable, or sudden death preceded by cardiac symptoms or signs


ABBREVIATIONS AND ACRONYMS

CHD = coronary heart disease

HDL-C = high-density lipoprotein cholesterol

LDL-C = low-density lipoprotein cholesterol

CENTRAL ILLUSTRATION The Race-Specific Association of HDL-C With CHD Risk



Zakai NA, et al. *J Am Coll Cardiol.* 2022;80(22):2104-2115.

Low high-density lipoprotein cholesterol (HDL-C) levels were detrimental only in White adults; high HDL-C levels were not protective in either race. CHD = coronary heart disease; REGARDS = REasons for Geographic and Racial Differences in Stroke.

without evidence of noncoronary causes.³ Non-CHD or MI-related deaths were censored.⁴ When nonfatal events were reported, medical records were retrieved for adjudication by trained clinicians following published guidelines.^{34,35} When fatal CHD events were reported, interviews with next of kin or proxies, review of medical records in the last year of life, death

certificates, and autopsy reports were used to determine whether the CHD event was the ultimate cause of death.

RISK FACTORS. Baseline blood samples were obtained after a 10- to 12-hour overnight fast. Samples were centrifuged within 2 hours of collection; serum and plasma were separated and shipped overnight to


the study biorepository at University of Vermont for storage or analysis. Upon arrival, samples were centrifuged at 30,000 g at 4 °C and either analyzed or stored at below -80 °C. Cholesterol, HDL-C, triglycerides and glucose were measured by colorimetric reflectance spectrophotometry using the Ortho Vitros Clinical Chemistry System 950IRC (Johnson and Johnson Clinical Diagnostics).³¹ LDL-C was calculated using the Friedewald equation.³⁶

Smoking status was modeled as current vs former/never, and body mass index was defined as the mass in kilograms divided by the height in meters squared measured at the in-home visit. Medications (statins and blood pressure medications) were defined from a medication inventory collected at the in-home visit. Blood pressure was the average of 2 measures after resting for 5 minutes at the in-home visit. Diabetes was self-reported diagnosis of diabetes, a fasting glucose ≥ 126 , a nonfasting glucose ≥ 200 , or use of antidiabetic medications including insulin.

STATISTICAL ANALYSIS. Participants with prior CHD were excluded. Baseline characteristics were summarized with mean \pm SD for continuous variables and n (%) for categorical variables. The standardized mean difference was calculated between Black and White participants as the difference in mean divided by the SD. Time to first CHD event, loss to follow-up (unable to contact because of illness, dementia, move, or withdrawal of consent by participant or proxy) or death was calculated from the baseline visit to compute the follow-up time for survival analyses. Details of the analytical approach are presented in the [Supplemental Appendix](#).

RESULTS

COHORT CHARACTERISTICS. Among 29,290 participants with follow-up in REGARDS, we excluded 5,389 participants with baseline CHD, thus leaving 23,901 participants in the analytical sample. Race-specific missingness is presented in [Supplemental Table 1](#). Of these, 57.7% identified as White and 58.3% as female ([Figure 1](#)). Black and White participants had comparable mean age, lipid profiles, smoking status, and hypertension and diabetes medication use ([Table 1](#)). Over a median follow-up of 10.7 years (IQR: 6.4-12.7 years), 1,615 CHD events occurred, of which 41.1% occurred among Black participants and 45.5% occurred among women ([Table 1](#)). Black and White men had comparable incident CHD rates, whereas Black women had a higher incident CHD rate than White women. More CHD events were fatal in Black men and women than in White men and women ([Table 1](#)).



LIPIDS PROFILES AND CHD RISK. We determined the association of plasma LDL-C, HDL-C, and triglycerides levels with CHD incidence. In model 2, every 1 SD increase in LDL-C (34 mg/dL) and triglyceride (82 mg/dL) levels were associated with a modest increase in CHD risk (HR: 1.05; 95% CI: 0.99-1.10, and HR: 1.09; 95% CI: 1.05-1.12, respectively) ([Table 2](#)). The detrimental association between increased LDL-C and triglycerides and CHD was maintained when the models were further adjusted for clinical factors (Model 3). In the unadjusted model, every 1-SD (16 mg/dL) increase in HDL-C levels was associated with decreased CHD risk (HR: 0.78; 95% CI: 0.74-0.83), although adjustment for clinical risk factors in Model 3 attenuated the association (HR: 0.95; 95% CI: 0.89-1.02) ([Table 2](#)).

The race-stratified survival estimates per sex-specific low, normal, and high HDL-C clinical categories displayed distinct profiles for White and Black participants ([Figure 2](#)). Low HDL-C levels were associated with poor CHD-free survival rates in White but not in Black participants (global log-rank $P < 0.001$). High HDL-C levels were associated with favorable CHD-free survival rates in White but not in Black participants ($P = 0.0052$) ([Figure 2](#)).

In unadjusted race-stratified spline models, the point estimate for lower HDL-C levels were associated with increased CHD risk in White but not in Black participants, and the race-specific association was

TABLE 1 Characteristics of REGARDS Participants

	Overall (N = 23,901)	Black (n = 10,095)	White (n = 13,806)
Male	9,949 (41.6)	3,661 (36.3)	6,288 (45.5)
Region			
Belt	8,262 (34.6)	3,388 (33.6)	4,874 (35.3)
Buckle	5,020 (21.0)	1,837 (18.2)	3,183 (23.1)
Nonbelt	10,619 (44.4)	4,870 (48.2)	5,749 (41.6)
Education			
Less than high school	2,733 (11.4)	1,872 (18.6)	861 (6.2)
High school	6,064 (25.4)	2,805 (27.8)	3,259 (23.6)
Some college	6,470 (27.1)	2,735 (27.1)	3,735 (27.1)
College and above	8,619 (36.1)	2,675 (26.5)	5,944 (43.1)
Age, y	64.1 ± 9.32	63.6 ± 9.25	64.4 ± 9.36
HDL, mg/dL	52.7 ± 16.25	53.9 ± 15.97	51.9 ± 16.40
HDL, mg/dL, M/F	46.17 ± 13.83/57.60 ± 16.19	48.33 ± 14.52/57.19 ± 15.87	44.94 ± 13.27/57.94 ± 16.44
LDL, mg/dL	116.5 ± 34.35	118.2 ± 36.05	115.3 ± 33.03
Triglycerides, mg/dL	129.7 ± 82.77	112.1 ± 73.68	142.2 ± 86.55
Cholesterol, mg/dL	195.2 ± 39.23	194.6 ± 40.48	195.6 ± 38.31
SBP, mm Hg	127.06 ± 16.46	130.29 ± 17.14	124.70 ± 15.52
DBP, mm Hg	76.70 ± 9.60	78.48 ± 9.96	75.40 ± 9.12
BMI, kg/m ²	29.2 ± 6.23	30.7 ± 6.70	28.2 ± 5.63
Sex-specific HDL categories			
Low	7,878 (34.6)	3,094 (32.6)	4,784 (35.9)
Normal	8,278 (36.3)	3,457 (36.5)	4,821 (36.2)
High	6,643 (29.1)	2,933 (30.9)	3,710 (27.9)
Current smoker	3,382 (14.2)	1,711 (17.0)	1,671 (12.1)
Taking hypertension medication	11,495 (50.1)	6,123 (63.0)	5,372 (40.6)
Diabetes	4,460 (19.4)	2,745 (28.4)	1,715 (12.8)
Taking dyslipidemia medication	6,672 (28.2)	2,728 (27.3)	3,944 (28.9)
Median follow-up, y	10.7	10.8	10.4
Total person-y follow-up	225,269	91,112	134,156
CHD events (women)	1,615 (736)	664 (358)	951 (378)
Total fatal CHD events (women)	555 (255)	280 (142)	275 (113)

Values are n (%) or median ± SD, unless otherwise indicated. HDL categories: Low ≤40 mg/dL for men, <50 mg/dL for women; normal 40-60mg/dL for men, 50-60 mg/dL for women; high >60 mg/dL. The table was constructed according to the STROBE (Strengthening The Reporting of Observational studies in Epidemiology) guidelines and omits P values.⁵⁹

BMI = body mass index; CHD = coronary heart disease; DBP = diastolic blood pressure; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; REGARDS = REasons for Geographic and Racial Differences in Stroke; SBP = systolic blood pressure.

maintained after adjusting for clinical and behavioral factors (**Figure 3**) (*P* values for race-spline term interaction: Model 1 *P* = 0.018, Model 2 *P* = 0.056, Model 3 *P* = 0.067).

In the unadjusted model, higher HDL-C levels were associated with reduced CHD risk in both White and Black individuals; after adjustment for clinical and behavioral factors, there was no association of higher HDL-C levels with CHD risk in both White and Black participants.

We next examined the association of clinical HDL-C categories with CHD risk stratified by race (**Figure 4**, **Supplemental Table 2**). Low HDL-C was associated with increased CHD risk in White (HR: 1.30; 95% CI: 1.13-1.50) but not in Black (HR: 0.97; 95% CI: 0.81-1.17) participants, whereas high HDL-C was associated with

reduced CHD risk in both Black (HR: 0.74; 95% CI: 0.61-0.91) and White (HR: 0.67; 95% CI: 0.56-0.81) participants only in the unadjusted model (*P* interaction = 0.007). After adjusting for clinical risk factors (Model 3), low HDL-C was associated with increased risk of CHD in White (HR: 1.22; 95% CI: 1.05-1.43) but not in Black (HR: 0.94; 95% CI: 0.78-1.14) individuals (*P* interaction = 0.08) and high HDL-C was no longer protective in either Black (HR: 0.91; 95% CI: 0.74-1.12) or White (HR: 0.96; 95% CI: 0.79-1.16) participants. We found no evidence for sex interaction in race stratified models (**Supplemental Table 3**).

SENSITIVITY ANALYSES. We fit the Model 2 within race strata separately to determine whether the differences observed remained when allowing other

predictors to vary between the race subgroups (Supplemental Table 4). Consistent with the imputation-derived results, the high HDL-C clinical category translated to protection in White but not in Black participants.

DISCUSSION

In REGARDS—a large contemporary biracial cohort—after adjusting for other risk factors, low HDL-C was associated with increased CHD risk in White but not Black participants, whereas high HDL-C was not associated with CHD risk in either group. Other lipid parameters, such as LDL-C and triglycerides, did not display race-specific behavior and were comparably associated with CHD risk in Black and White participants. Our race-dependent observations indicate that the underlying biologic mechanism by which HDL-C associates with incident CHD in White and Black participants is different from that of other lipid risk factors. Although HDL-C clinical risk category cutoffs are well established for White populations, our findings expose the weaknesses in their use, because such categories might not apply to Black men and women, reducing their value in CHD risk assessment.

Previous epidemiological studies including mostly White participants established that higher HDL-C is associated with a reduced risk of incident CHD, although the strength of this association is unclear for other populations. Although the inverse relationship between HDL-C and CHD was believed to be linear,^{14,28} several cohorts have revealed a leveling of risk at around 40 mg/dL.³⁷ Recent evidence from 2 large population-based Danish cohorts³⁸ and in the MESA (Multi-Ethnic Study of Atherosclerosis)³⁹ supports a U-shaped association between HDL-C and CHD risk. Most evidence stems from ethnically White-enriched cohorts; therefore, it is unknown whether the U-shaped association applies to all races and ethnicities. In the Dallas Heart Study, with 46% Black participants, HDL-C was inversely associated with incident CHD among non-Black but not in Black participants.²⁵ A prior analysis in a cancer-focused REGARDS sub-study did report that HDL-C of 30 to 40 mg/dL—compared with HDL-C >40 mg/dL—was associated with lower CHD risk in Black but not in White adults, but did not report on the association of all established HDL-C clinical categories with CHD risk.²⁶

Further, we reported that triglycerides to HDL-C ratio was a CHD risk predictor in White but not in Black adults of the REGARDS—an effect driven by the lack of association of HDL-C with CHD in Black adults.⁴⁰ LDL-C rather than total cholesterol is more likely to display racial differences because it is a

TABLE 2 Association of HDL-C per SD and Common Risk Factors With CHD

	Univariate ^a	Model 2 ^b	Model 3 ^c
HDL-C, per 16 mg/dL	0.78 (0.74-0.83)	0.86 (0.81-0.91)	0.95 (0.89-1.02)
LDL-C, per 34 mg/dL	1.01 (0.96-1.06)	1.05 (0.99-1.10)	1.10 (1.05-1.17)
Triglycerides, per 62 mg/dL	1.11 (1.08-1.14)	1.09 (1.05-1.12)	1.05 (1.01-1.10)
Age, y	1.05 (1.04-1.06)	1.05 (1.05-1.06)	1.05 (1.05-1.06)
Male	1.64 (1.49-1.81)	1.52 (1.36-1.70)	1.64 (1.46-1.84)
Black	1.03 (0.94-1.14)	1.19 (1.07-1.32)	0.88 (0.79-0.99)

Values are HR (95% CI). Staged Cox proportional hazards models for the association of HDL-C with incident CHD were applied, without race-lipid interactions. HR for HDL, LDL, and triglycerides were calculated per SD increment. Male HR is calculated in reference to female, and Black HR is calculated in reference to White. ^aUnivariate unadjusted estimates for each predictor. ^bModel 2 estimates are adjusted for LDL-C, triglycerides, age, sex, race, and region. ^cModel 3 estimates are additionally adjusted for smoking, BMI, SBP, diabetes, statins, and hypertensive medication.

Abbreviations as in Table 1.


metric sensitive to access to care. In our cohort, lipid-lowering medication use revealed modest but significant disparities between White and Black adults: among all of the adults on medication, 27.3% were Black participants vs 28.9% White participants. This aligns with the slightly elevated plasma LDL-C levels in Black participants. Although the adjustment for calculated LDL-C (which uses a formula inclusive of triglycerides) might mask the true point estimates for triglycerides, the fact that the point estimates do not vary between univariate and the most complex model suggests that the LDL-C adjusting has a minor or null effect.

Collectively, the results support the presence of racial differences that affect the inverse association of HDL-C and incident CHD.


What we have learned from the spline models and from the clinical cutoff point estimates aligns with low HDL-C being detrimental in White adults and not predictive in Black adults.

So far, data from multiethnic population-based studies and clinical cohorts have not provided a consistent conclusion on the role of HDL-C as predictor of CVD risk in Black participants. In some cohorts, HDL-C levels were lower,⁴¹ similar,³ or higher in Black than in White participants.⁴²⁻⁴⁴ Although Mendelian randomization studies demonstrate that mutations in several genes linked to elevated HDL-C concentrations are not associated with reduced risk of CHD,⁴⁵ most of these studies were conducted with European cohorts using 5-point ancestry principal component adjustment to correct for population architecture.^{46,47} Causal variants at individual loci can be specific for certain ethnicities.⁴⁸ Of the identified HDL-C-related loci, only cholesteryl ester transfer protein has been validated in a Japanese cohort⁴⁹—interestingly, in cholesteryl ester transfer protein mutation. Race- and ethnicity-specific Mendelian

FIGURE 2 Estimates for Cumulative Incidence of CHD Events and CHD Death




Number at risk		0	2	4	6	8	10	12
Low	4,784	4,507	4,123	3,692	3,235	2,762	1,513	
Normal	4,821	4,598	4,269	3,880	3,489	3,045	1,800	
High	3,710	3,573	3,333	3,035	2,790	2,412	1,432	
Cumulative number of events		0	2	4	6	8	10	12
Low	0	76	155	219	281	333	383	
Normal	0	58	105	167	221	268	315	
High	0	21	48	80	100	128	155	



Number at risk		0	2	4	6	8	10	12
Low	3,094	2,839	2,566	2,255	1,952	1,631	854	
Normal	3,457	3,184	2,863	2,540	2,230	1,895	1,094	
High	2,933	2,722	2,465	2,175	1,913	1,650	998	
Cumulative number of events		0	2	4	6	8	10	12
Low	0	35	72	116	143	164	196	
Normal	0	46	106	151	185	211	238	
High	0	24	50	83	104	130	145	

(A) White adults, (B) Black adults. Kaplan-Meier estimates were calculated per clinical high-density lipoprotein (HDL) categories. Participants were classified by sex: low (reference): <40 mg/dL for men and <50 mg/dL for women; normal: 40-59 mg/dL for men, 50-59 mg/dL for women; and high: ≥60 mg/dL. P values are from log-rank test. CHD = coronary heart disease.

FIGURE 3 Predicted Relative HR Curves From Spline Regression Analyses




Cubic splines were fit for high-density lipoprotein (HDL) cholesterol within each race group, with relative hazard curves for coronary heart disease incidence compared with median HDL cholesterol of 50 mg/dL. HRs evaluated at median or reference groups of all other model predictors. Shaded area represents 95% CI. Model 1 is unadjusted. Model 2 estimates were adjusted for low-density lipoprotein cholesterol, triglycerides, age, sex, race, and region. Model 3 estimates were additionally adjusted for smoking, body mass index, systolic blood pressure, diabetes, statins, and hypertensive medication.

randomization studies may help extend and refine our understanding between plasma HDL-C levels and CHD risk in diverse populations.

Measures other than HDL cholesterol content, such as HDL particle number, proteomic composition, and anti-inflammatory, antioxidant, and sterol efflux

activities are all candidates to explain the race-specific association of HDL with CHD risk.^{24,25,50-53}

For example, greater HDL cholesterol efflux capacity, independent of either HDL-C or APOAI (the major structural protein of HDL), is associated with a lower prevalence and incidence of atherosclerotic vascular



disease in multiple cohorts.^{24,51,52} More recently, in the PREVENT (Prevention of Renal and Vascular End Stage Disease) study, the anti-inflammatory capacity of HDL (independent of its sterol efflux capacity) was inversely associated with incident vascular events,⁵³ and the authors showed that inclusion of this metric in the risk prediction formula improves CHD risk assessment. It is yet to be determined, however, if these novel HDL measures display race-specific associations with CHD outcomes and whether they can indeed improve risk assessment in all ethnicities.

Race dependent associations of HDL-C with CHD risk may affect the performance of CHD risk prediction equations. Our findings using a contemporary cohort raise caution for the widely used CHD risk

algorithms such as Framingham,⁵⁴ PROCAM,⁵⁵ Pooled Cohort,⁵⁶ and MESA.²⁰ Assuming a linear relationship, these algorithms reward for high HDL-C and penalize for low HDL-C. In addition, though race is a component of the formula, the interaction of specific components, such as HDL-C, is not. For example, according to the MESA risk calculator,⁵⁷ a 50-year-old woman with no clinical risk factors and no family history of heart disease, total cholesterol of 170 mg/dL, and systolic blood pressure of 120 mm Hg has a 10-year CHD risk of 1.3%, 1.0%, and 0.5% for HDL-C levels of 30, 50, and 105 mg/dL respectively—and race information does not change a risk estimate predicting >3-fold decrease in risk with the doubling of HDL-C. Our results suggest that although low

HDL-C is detrimental only in White adults, high HDL-C does not afford protection for both races.

Even though the possibility of chance influencing our findings cannot be completely excluded, it is more likely that our results really identify a race-specific effect and indicate a need for race-specific guidelines in CVD risk prediction. Future efforts to calibrate and validate risk algorithms require continuous data input encompassing all races and ethnicities.

The contribution of HDL-C to overall CHD risk has been variable and modest; yet, we have a poor understanding of the competing risk—which is not discussed in the clinic or in the CHD risk equations. Given that overall CHD deaths are low in REGARDS and favor Black participants, and that low HDL-C is not a leading risk factor for mortality, we are less likely to overestimate its contribution to CHD risk. Therefore, a competing risk analysis, which is conducted to address risk overestimation,⁵⁸ might be insightful in larger cohorts with higher event rates.

Our current understanding of how HDL-C contributes to CHD risk is primarily shaped by the Framingham heart study, where all cohorts (original, offspring, spouses) are 100% White American. Collective data from recent years suggest that we should develop a population-wide risk estimation algorithm that works in other races as well. Race is a complex metric defined both by a social construct and a genetic construct, making it challenging to capture its full spectrum in a risk prediction algorithm. Further, modeling the race-HDL-C interaction is particularly challenging given that the association of HDL-C with CHD risk is likely ethnicity-dependent. Our data suggest that the use of low HDL-C is informative in White adults but not in Black adults and the use of high HDL-C might not be helpful in either race. Although we need to gather further population-based evidence, our data support the notion that the value of high HDL-C in risk prediction algorithms should be demoted.

STUDY LIMITATIONS. Because of this study's observational design, caution must be applied when drawing causal inferences. Note that the original study¹⁴ assessing HDL-C as a risk factor for CHD was also observational. The dispersed nature of the REGARDS cohort is both a strength and a weakness. The population in the REGARDS cohort was recruited from the entire contiguous United States, having participants in 62% of U.S. counties. Although this distribution allows for generalizability of the findings, participants were not clinically assessed as in-depth at baseline as they were in other cohorts with discrete coordinating centers.³⁹ The geographic

breadth of REGARDS is its greatest strength, but it may have affected the completeness of CHD event ascertainment. However, the geographic and racial diversity of REGARDS allows greater generalizability of the current findings to the U.S. population. The limited number of fatal CHD events per race prevents from assessing race dependent association of HDL-C with fatal CHD.

CONCLUSIONS

In a contemporary biracial cohort, low HDL-C levels were associated with increased CHD risk in White but not in Black adults. High HDL-C levels were not protective for either race. Our findings support the need for the calibration of the current risk algorithms.

ACKNOWLEDGMENTS The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. Original illustrations were have been created with BioRender.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This research project is supported by cooperative agreement U01 NS041588 co-funded by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging, National Institutes of Health, Department of Health and Human Service; and by R01HL136373 (to Drs Zakai, Minnier, and Pamir) and R01 HL080477 (to Dr Safford) from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the National Institute on Aging. Representatives of the NINDS were involved in the review of the manuscript but were not directly involved in the collection, management, analysis or interpretation of the data. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Nathalie Pamir, Knight Cardiovascular Institute, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, HRC5N, Portland, Oregon 97239, USA. E-mail: pamir@ohsu.edu.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: An inverse relationship between plasma levels of HDL-C and atherosclerotic risk does not apply uniformly across racially defined populations. High HDL-C levels may not be protective in either White or Black adults, and low HDL-C levels are associated with increased cardiovascular risk only in White adults.

TRANSLATIONAL OUTLOOK: Further research is needed to understand the mechanisms linking HDL-cholesterol to cardiovascular risk and how these are modified by race.

REFERENCES

- Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation*. 2020;141(9):e139–e596. <https://doi.org/10.1161/cir.0000000000000757>
- Blackwell D, Villarreal M. Tables of Summary Health Statistics for US Adults: 2017 National Health Interview Survey (Table A-6). National Center for Health Statistics, 2018. Accessed June 6, 2019. <https://www.cdc.gov/nchs/nhis/shs/tables.htm>
- Colantonio LD, Gamboa CM, Richman JS, et al. Black-White differences in incident fatal, nonfatal, and total coronary heart disease. *Circulation*. 2017;136(2):152–166. <https://doi.org/10.1161/circulationaha.116.025848>
- Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. *JAMA*. 2012;308(17):1768–1774. <https://doi.org/10.1001/jama.2012.14306>
- Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. *Circulation*. 2005;111(10):1233–1241. <https://doi.org/10.1161/01.cir.0000158136.76824.04>
- Mensah GA. Eliminating disparities in cardiovascular health. *Circulation*. 2005;111(10):1332–1336. <https://doi.org/10.1161/01.cir.0000158134.24860.91>
- U.S. Department of Health and Human Services. HHS Action plan to reduce racial and ethnic health disparities: implementation progress report 2011–2014. US Department of Health and Human Services, 2011. Accessed October 2, 2022. <https://aspe.hhs.gov/reports/hhs-action-plan-reduce-racial-ethnic-health-disparities-implementation-progress-report-2011-2014>
- Institute of Medicine (US). Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. In: Smedley BD, Stith AY, Nelson AR, eds. *Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care*. National Academies Press (US); 2003.
- National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143–3421.
- Frank ATH, Zhao B, Jose PO, Azar KMJ, Fortmann SP, Palaniappan LP. Racial and ethnic differences in dyslipidemia patterns. *Circulation*. 2014;129(5):570–579. <https://doi.org/10.1161/circulationaha.113.005757>
- Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation*. 2019;139(10):e56–e66. <https://doi.org/10.1161/cir.0000000000000659>
- Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. *Circulation*. 2017;136(21):e393–e423. <https://doi.org/10.1161/cir.0000000000000534>
- Howard G, Lackland DT, Kleindorfer DO, et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. *JAMA Intern Med*. 2013;173(1):46–51. <https://doi.org/10.1001/2013.jamainternmed.857>
- Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease the Framingham study. *Am J Med*. 1977;62(5):707–714. [https://doi.org/10.1016/0002-9343\(77\)90874-9](https://doi.org/10.1016/0002-9343(77)90874-9)
- Zhang B, Menzin J, Friedman M, Korn JR, Burge RT. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. *Curr Med Res Opin*. 2008;24(9):2711–2717. <https://doi.org/10.1185/03007990802363198>
- Jacobsen BK, Thelle DS. The Tromsø Heart Study: food habits, serum total cholesterol, HDL cholesterol, and triglycerides. *Am J Epidemiol*. 1987;125(4):622–630. <https://doi.org/10.1093/oxfordjournals.aje.a114575>
- Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). *Am J Cardiol*. 1992;70(7):733–737. [https://doi.org/10.1016/0002-9149\(92\)90550-i](https://doi.org/10.1016/0002-9149(92)90550-i)
- Assmann G, Schulte H, Eckardstein A von, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis*. 1996;124:S11–S20. [https://doi.org/10.1016/0021-9150\(96\)05852-2](https://doi.org/10.1016/0021-9150(96)05852-2)
- Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. *Arterioscler Thromb Vasc Biol*. 1997;17(1):107–113. <https://doi.org/10.1161/01.atv.17.1.107>
- McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). *J Am Coll Cardiol*. 2015;66(15):1643–1653. <https://doi.org/10.1016/j.jacc.2015.08.035>
- Colantonio LD, Bittner V, Reynolds K, et al. Association of serum lipids and coronary heart disease in contemporary observational studies. *Circulation*. 2016;133(3):256–264. <https://doi.org/10.1161/circulationaha.115.011646>
- Jones DW, Chambless LE, Folsom AR, et al. Risk factors for coronary heart disease in African Americans: the Atherosclerosis Risk in Communities Study, 1987–1997. *Arch Intern Med*. 2002;162(22):2565–2571. <https://doi.org/10.1001/archinte.162.22.2565>
- Virani SS, Catellier DJ, Pompeii LA, et al. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk In Communities (ARIC) carotid MRI study. *Atherosclerosis*. 2011;219(2):596–602. <https://doi.org/10.1016/j.atherosclerosis.2011.08.001>
- Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *N Engl J Med*. 2011;364(2):127–135. <https://doi.org/10.1056/nejmoa1001689>
- Chandra A, Neeland IJ, Das SR, et al. Relation of Black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). *Am J Cardiol*. 2015;115(7):890–894. <https://doi.org/10.1016/j.amjcard.2015.01.015>
- Penson P, Long LD, Howard G, et al. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. *Cardiovasc Res*. 2018;115(1):204–212. <https://doi.org/10.1093/cvr/cvy198>
- Steege WA van der, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk the IDEAL and EPIC-Norfolk Studies. *J Am Coll Cardiol*. 2008;51(6):634–642. <https://doi.org/10.1016/j.jacc.2007.09.060>
- Collaboration E, Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*. 2009;302(18):1993–2000. <https://doi.org/10.1001/jama.2009.1619>
- Howard VJ, Woolson RF, Egan BM, et al. Prevalence of hypertension by duration and age at exposure to the stroke belt. *J Am Soc Hypertens*. 2010;4(1):32–41. <https://doi.org/10.1016/j.jash.2010.02.001>
- Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. *Neuroepidemiology*. 2005;25(3):135–143. <https://doi.org/10.1159/000086678>
- Colantonio LD, Gamboa CM, Kleindorfer DO, et al. Stroke symptoms and risk for incident coronary heart disease in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. *Int J Cardiol*. 2016;220:122–128. <https://doi.org/10.1016/j.ijcard.2016.06.030>
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61(4):344–349. <https://doi.org/10.1016/j.jclinepi.2007.11.008>

33. Safford MM, Gamboa CM, Durant RW, et al. Race-sex differences in the management of hyperlipidemia: the REasons for Geographic And Racial Differences in Stroke Study. *Am J Prev Med.* 2015;48(5):520-527. <https://doi.org/10.1016/j.amepre.2014.10.025>
34. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. *Circulation.* 2003;108(20):2543-2549. <https://doi.org/10.1161/01.cir.0000100560.46946.ea>
35. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. *Circulation.* 2007;116(22):2634-2653. <https://doi.org/10.1161/circulationaha.107.187397>
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18(6):499-502. <https://doi.org/10.1093/clinchem/18.6.499>
37. Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. *J Am Heart Assoc.* 2014;3(2):e000519. <https://doi.org/10.1161/jaha.113.000519>
38. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J.* 2017;38(32):2478-2486. <https://doi.org/10.1093/eurheartj/ehx163>
39. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol.* 2012;60(6):508-516. <https://doi.org/10.1016/j.jacc.2012.03.060>
40. Tejera C, Minnif J, Fazio S, et al. High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults. *Am J Prev Cardiol.* 2021;7:100198. <https://doi.org/10.1016/j.ajpc.2021.100198>
41. Wilson P, Savage DD, Castelli WP, Garrison RJ, Donahue RP, Feinleib M. HDL-cholesterol in a sample of black adults: the Framingham minority study. *Metabolism.* 1983;32(4):328-332. [https://doi.org/10.1016/0026-0495\(83\)90039-2](https://doi.org/10.1016/0026-0495(83)90039-2)
42. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med.* 2003;163(4):427-436. <https://doi.org/10.1001/archinte.163.4.427>
43. Metcalf PA, Sharrett AR, Folsom AR, et al. African American-White differences in lipids, lipoproteins, and apolipoproteins, by educational attainment, among middle-aged adults: the Atherosclerosis Risk in Communities Study. *Am J Epidemiol.* 1998;148(8):750-760. <https://doi.org/10.1093/oxfordjournals.aje.a009696>
44. Carroll MD, Kit BK, Lacher DA, Yoon SS. Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012. *NCHS Data Brief.* 2013;(132):1-8.
45. Acker BAC van, Botma G-J, Zwinderman AH, et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. *Atherosclerosis.* 2008;200(1):161-167. <https://doi.org/10.1016/j.atherosclerosis.2007.11.019>
46. Voight B, Peloso G, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. *Lancet.* 2012;380(9841):572-580. [https://doi.org/10.1016/S0140-6736\(12\)60312-2](https://doi.org/10.1016/S0140-6736(12)60312-2)
47. Nomura A, Won H-H, Khera AV, et al. Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. *Circ Res.* 2017;121(1):81-88. <https://doi.org/10.1161/circresaha.117.311145>
48. Davies NM, Holmes MV, Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2017;362:k601. <https://doi.org/10.1136/bmj.k601>
49. Takeuchi F, Isono M, Katsuya T, et al. Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals. *PLoS One.* 2012;7(9):e46385. <https://doi.org/10.1371/journal.pone.0046385>
50. Singh K, Chandra A, Sperry T, et al. Associations between HDL particles and ischemic events by vascular domain, gender, and ethnicity: a pooled cohort analysis. *Circulation.* 2020;142(7):657-669. <https://doi.org/10.1161/circulationaha.120.045713>
51. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. *N Engl J Med.* 2014;371(25):2383-2393. <https://doi.org/10.1056/nejmoa1409065>
52. Shea S, Stein JH, Jorgensen NW, et al. Cholesterol mass efflux capacity, incident cardiovascular disease, and progression of carotid plaque. *Arteriosclerosis Thrombosis Vasc Biol.* 2018;39(1):89-96. <https://doi.org/10.1161/atvbaha.118.311366>
53. Jia C, Anderson J, Gruppen EG, et al. High-density lipoprotein anti-inflammatory capacity and incident cardiovascular events. *Circulation.* 2021;143(20):1935-1945. <https://doi.org/10.1161/circulationaha.120.050808>
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA.* 2001;285(19):2486-2497. <https://doi.org/10.1001/jama.285.19.2486>
55. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. *Circulation.* 2002;105(3):310-315. <https://doi.org/10.1161/hc0302.102575>
56. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63(25 Pt B):2935-2959.
57. MESA 10-year CHD risk with coronary artery Calcification. The Multi-Ethnic Study of Atherosclerosis. Accessed October 2, 2022. <https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx>
58. Roetker NS, Gilbertson DT, Weinhandl ED. A brief introduction to competing risks in the context of kidney disease epidemiology. *Kidney360.* 2022;3(4):740-743. <https://doi.org/10.34067/kid.0007382021>
59. Rosendaal FR, Reitsma PH. No P please. *J Thromb Haemost.* 2016;14(8). <https://doi.org/10.1111/jth.13422>, 1493-1493.
-
- KEY WORDS** CHD, cholesterol, HDL, health disparities, myocardial infarction, public health
-
- APPENDIX** For details regarding a full list of participating REGARDS investigators, an expanded Methods section, and supplemental tables, please see the online version of this paper.